Diagnostic Center | August 04, 2022
Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March’22)
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
This state-of-art technology will help pulmonologists to diagnose lung cancer in the very early stages helping the patient get an early surgical resection
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
